Insights

Strategic Funding Series B funding and a reported revenue range indicate growing clinical-stage potential and financial runway, suggesting staying power for partnership discussions, joint development, or out-licensing opportunities around INV-102.

Clinical Differentiation First-in-class mechanism targeting genomic dysfunction in diabetic eye diseases presents a unique value proposition that can be emphasized in pitching to ophthalmology and pharma partners seeking novel, mechanism-based therapies with potential to address multiple ocular conditions.

Targeted Market Evidence from Phase 2 in diabetic eye diseases and signals in AIK imply a strategic entry point in diabetic retinopathy, keratopathy, and related ocular conditions, with potential for expansion into companion diagnostics or biomarker-driven trials.

Growth Levers Moderate headcount and early-stage revenue suggest readiness for strategic collaborations, licensure agreements, or co-development deals with larger pharma players to accelerate late-stage development and commercialization.

Technology & Ops Existing tech stack and web-enabled operations indicate a lean, digital-forward organization that can leverage partnerships for digital health, data integration, and scalable manufacturing discussions, while highlighting readiness for regulatory filings.

Similar companies to Invirsa, Inc

Invirsa, Inc Tech Stack

Invirsa, Inc uses 8 technology products and services including Webpack, Google Workspace, React, and more. Explore Invirsa, Inc's tech stack below.

  • Webpack
    Development
  • React
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • Adobe Fonts
    Web Fonts
  • Gatsby
    Web Frameworks
  • Apache
    Web Servers
  • Apache HTTP Server
    Web Servers

Invirsa, Inc's Email Address Formats

Invirsa, Inc uses at least 1 email format:
Invirsa, Inc Email FormatsExamplePercentage
FLast@invirsa.comJDoe@invirsa.com
100%

Frequently Asked Questions

What is Invirsa, Inc's official website and social media links?

Minus sign iconPlus sign icon
Invirsa, Inc's official website is invirsa.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Invirsa, Inc generate?

Minus sign iconPlus sign icon
As of November 2026, Invirsa, Inc's annual revenue is estimated to be $1M - $10M.

What is Invirsa, Inc's NAICS code?

Minus sign iconPlus sign icon
Invirsa, Inc's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Invirsa, Inc have currently?

Minus sign iconPlus sign icon
As of November 2026, Invirsa, Inc has approximately 11 employees across 1 continents, including North America. Key team members include Chief Financial Officer: R. W., Senior Director Of Chemistry, Manufacturing And Controls: J. R. and Project Manager: S. M. Explore Invirsa, Inc's employee directory with LeadIQ.

What industry does Invirsa, Inc belong to?

Minus sign iconPlus sign icon
Invirsa, Inc operates in the Pharmaceutical Manufacturing industry.

What technology does Invirsa, Inc use?

Minus sign iconPlus sign icon
Invirsa, Inc's tech stack includes Webpack, Google Workspace, React, jQuery, Adobe Fonts, Gatsby, Apache and Apache HTTP Server.

What is Invirsa, Inc's email format?

Minus sign iconPlus sign icon
Invirsa, Inc's email format typically follows the pattern of FLast@invirsa.com. Find more Invirsa, Inc email formats with LeadIQ.

How much funding has Invirsa, Inc raised to date?

Minus sign iconPlus sign icon
As of November 2026, Invirsa, Inc has raised $16M in funding. The last funding round occurred on Jun 14, 2023 for $7.7M.
Invirsa, Inc logo

Invirsa, Inc

Pharmaceutical ManufacturingOhio, United States11-50 Employees

Invirsa, Inc is a clinical-stage pharmaceutical company focused on developing therapies for ocular diseases rooted in genomic dysfunction. Its lead candidate, INV-102, targets diabetic eye conditions by countering pathological PARylation to restore genome architecture and promote repair, aiming to improve healing in conditions such as non-healing corneal ulcers and keratopathy. The company positions its work at the intersection of molecular biology and ophthalmology, seeking to address an underlying cause of vision-related diseases rather than treating symptoms alone. Based in Columbus, Ohio, Invirsa operates in the pharmaceutical manufacturing space with a focus on small-molecule therapeutics and related ocular indications. The organization is positioned as a specialized, early-stage enterprise pursuing a targeted portfolio grounded in genomic mechanisms that influence tissue repair and immune-modulatory effects in eye diseases. A recent development highlights progress in its clinical program, with Phase 2 data indicating statistically significant improvements in visual acuity for diabetic subjects, reflecting mechanism-specific effects observed in its trials.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
11-50

Section iconFunding & Financials

  • $16M

    Invirsa, Inc has raised a total of $16M of funding over 5 rounds. Their latest funding round was raised on Jun 14, 2023 in the amount of $7.7M as a Series B.

  • $1M - $10M

    Invirsa, Inc's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.